Last update May 28, 2019
We do not have alternatives for Technetium 99m Mertiatide (MAG3) .
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Technetium 99m Mertiatide (MAG3) is also known as
Technetium 99m Mertiatide (MAG3) in other languages or writings:
Technetium 99m Mertiatide (MAG3) belongs to this group or family:
Main tradenames from several countries containing Technetium 99m Mertiatide (MAG3) in its composition:
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Metastable Technetium 99 (99mTc) is a radioactive isotope that emits gamma radiation. Its radioactive decay half-life is 6.0 hours.
After radioactive labelling with a sodium pertechnetate (Tc 99m) solution, the mertiatide (Tc 99m) test solution obtained is used in renal scintigraphy.
0.071% of the administered dose is excreted in breast milk (Leide 2016, Liepe 2016).
Breastfeeding interruption or close contact avoidance times are calculated so that the infant is not exposed to more than 1 millisievert (1 mSv = 0.1 rem) of radiation (ARSAC 2019, US.NCR 2016, ICRP 2008, Stabin 2000). An adult receives between 5 and 10 mSv annually from environmental radiation.
The main regulatory agencies which manage radioactive substances and experts consider that breastfeeding can be resumed immediately after a diagnostic test with Tc 99m mertiatide (Mitchell 2019, ARSAC 2019 p51, ICRP 2008 p163, Stabin 2000, Evans 1993).
If the dose administered was ≥ 200 MBq, a 2-hour interruption is recommended (ARSAC 2019 p51).
Some agencies (ARSAC 2019, ICRP 2008) consider it more prudent to discontinue breastfeeding for about 4 hours, expressing breast milk once and instead offering milk previously expressed and stored in a refrigerator prior to testing.
Milk expressed after the scintigraphy can be frozen and used after 10 radioactive half lives: 10 x 6.0 = 60 hours = 3 days (Hale 2017, p.2019).
Close contact with the infant need not be avoided (Mountford 1999).
See below the information of these related products: